Pulmonx Stock Price, News & Analysis
Company Description
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD), with a particular emphasis on patients suffering from severe emphysema. The company develops and markets medical devices and related technologies that are designed to assess and treat patients who remain profoundly symptomatic despite medical management.
According to company disclosures, Pulmonx’s solutions include the Zephyr® Endobronchial Valve, the Chartis® Pulmonary Assessment System, the LungTraX™ Platform, and StratX® Lung Analysis Reports. These technologies are designed to work together to identify appropriate candidates and provide a minimally invasive treatment option for severe emphysema/COPD. Pulmonx has stated that it received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.”
Core products and technologies
The company describes its primary offerings as:
- Zephyr Endobronchial Valve – a minimally invasive device intended to treat patients with severe emphysema/COPD who remain significantly symptomatic despite medical therapy. The Zephyr Valve is commercially available in more than 25 countries and is described by the company as being included in global treatment guidelines and widely considered a standard of care treatment option for improving breathing, activity, and quality of life in patients with severe emphysema.
- Chartis Pulmonary Assessment System – a system designed to assess patients’ lungs to help determine suitability for treatment with the Zephyr Valve.
- LungTraX Platform – a platform referenced by the company as part of its suite of tools to assess and treat severe emphysema/COPD patients.
- StratX Lung Analysis Reports – analysis reports described by the company as part of its tools for evaluating lung condition in emphysema/COPD patients.
Earlier descriptions also reference the StratX® Lung Analysis Platform, reflecting Pulmonx’s focus on imaging and analysis tools that support patient selection and treatment planning for emphysema procedures.
Business model and revenue sources
Based on prior company descriptions, Pulmonx generates revenue through the sale of its products to distributors and hospitals. The company has identified the United States as a key revenue-generating market and also reports revenue from regions including Europe, the Middle East and Africa, Asia Pacific, and other regions
Pulmonx’s financial statements and earnings releases highlight revenue from its commercial activities, cost of goods sold, gross profit, operating expenses, and measures such as Adjusted EBITDA. The company also discusses constant currency revenue growth to illustrate performance excluding foreign exchange effects.
Clinical and regulatory positioning
Pulmonx emphasizes that the Zephyr Valve received FDA pre-market approval after being designated a “breakthrough device”. The company states that the Zephyr Valve is commercially available in more than 25 countries and is included in global treatment guidelines. It is described as being widely considered a standard of care treatment option for improving breathing, activity, and quality of life in patients with severe emphysema.
This positioning underscores Pulmonx’s focus on severe emphysema/COPD patients who remain symptomatic despite medical management, and on providing physicians with tools to identify appropriate candidates and deliver minimally invasive lung volume reduction procedures.
Operations and corporate developments
Pulmonx files periodic financial reports and current reports with the U.S. Securities and Exchange Commission (SEC). In its earnings releases, the company discusses revenue trends, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA. It explains the use of non-GAAP measures, including constant currency calculations and Adjusted EBITDA, as supplemental ways of viewing aspects of its operations alongside GAAP results.
The company has also reported management changes via Form 8-K filings, including the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. These filings describe executive transitions, related compensation arrangements, and equity awards, and reference Pulmonx’s severance and change in control plan and indemnification agreements.
In addition, Pulmonx has disclosed inducement equity awards granted under a 2025 Inducement Plan, including restricted stock units (RSUs) and performance stock units (PSUs) granted to new employees in accordance with Nasdaq Listing Rule 5635(c)(4). These awards are subject to time-based vesting conditions and, for PSUs, stock price performance conditions based on the average closing price of the company’s common stock over a specified trading period.
Capital markets and investor engagement
Pulmonx’s common stock trades on the Nasdaq under the ticker symbol LUNG. The company participates in investor conferences and hosts quarterly earnings conference calls, as described in its news releases. These events typically cover financial results, revenue guidance, gross margin expectations, and operating expense outlook, as well as management’s commentary on commercial execution and adoption of Zephyr Valve procedures.
The company’s news releases also reference participation in healthcare and growth conferences hosted by financial institutions, where management presents to investors and conducts meetings. Webcasts of these events are made available through the investors section of Pulmonx’s website, according to the company’s announcements.
Geographic footprint and markets
In its public statements, Pulmonx identifies the United States as a key revenue-generating market and reports separate figures for U.S. and international revenue. International revenue is reported across regions that include Europe, the Middle East and Africa, and Asia Pacific, among others. The company links international revenue growth to global adoption of Zephyr Valve procedures.
The Zephyr Valve’s commercial availability in more than 25 countries, as stated by Pulmonx, indicates a presence in multiple healthcare systems where COPD and emphysema treatments are delivered. The company also notes that its products are included in global treatment guidelines, which it associates with the device being widely considered a standard of care option for certain severe emphysema patients.
Use of non-GAAP metrics
In its earnings releases, Pulmonx explains that it uses non-GAAP financial measures such as Adjusted EBITDA and constant currency revenue growth as supplemental metrics. Adjusted EBITDA is defined by the company as earnings before interest income or expense, taxes, depreciation and amortization, stock-based compensation, and certain non-recurring or one-time items not reflective of ongoing core business operations, such as impairment charges. Constant currency calculations are described as showing current period revenues as if foreign exchange rates were the same as in the comparable prior-year period.
The company states that these non-GAAP measures are intended to provide an additional way of viewing aspects of its operations and to help management and investors evaluate performance and financial trends alongside GAAP results.